Key clinical point: The Bruton tyrosine kinase (BTK) inhibitor zanubrutinib appears safe and effective for patients with B-cell malignancies.
Major finding: The overall response rate among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) was 96.2%.
Study details: A phase 1, open-label, dose-escalation/expansion study involving 144 patients with B-cell malignancies.
Disclosures: The study was funded by BeiGene USA, which is developing the drug. The investigators reported relationships with the study sponsor, as well as Janssen, Pharmacyclics, AbbVie, and others.
Tam CSL et al. Blood. 2019 Jul 24. doi: 10.1182/blood.2019001160.